DK1141014T3 - Insulinlignende vækstfaktor (IGF) i mutantvariant - Google Patents
Insulinlignende vækstfaktor (IGF) i mutantvariantInfo
- Publication number
- DK1141014T3 DK1141014T3 DK00901397T DK00901397T DK1141014T3 DK 1141014 T3 DK1141014 T3 DK 1141014T3 DK 00901397 T DK00901397 T DK 00901397T DK 00901397 T DK00901397 T DK 00901397T DK 1141014 T3 DK1141014 T3 DK 1141014T3
- Authority
- DK
- Denmark
- Prior art keywords
- igf
- insulin
- growth factor
- mutant variant
- mutant
- Prior art date
Links
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title abstract 4
- 102000013275 Somatomedins Human genes 0.000 title 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 2
- 239000004471 Glycine Substances 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11501099P | 1999-01-06 | 1999-01-06 | |
US17026199P | 1999-12-09 | 1999-12-09 | |
PCT/US2000/000199 WO2000040613A1 (en) | 1999-01-06 | 2000-01-05 | Insulin-like growth factor (igf) i mutant variants |
EP00901397A EP1141014B1 (de) | 1999-01-06 | 2000-01-05 | Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i) |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1141014T3 true DK1141014T3 (da) | 2005-04-11 |
Family
ID=26812755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00901397T DK1141014T3 (da) | 1999-01-06 | 2000-01-05 | Insulinlignende vækstfaktor (IGF) i mutantvariant |
Country Status (12)
Country | Link |
---|---|
US (3) | US6403764B1 (de) |
EP (1) | EP1141014B1 (de) |
JP (2) | JP3971108B2 (de) |
AT (1) | ATE284415T1 (de) |
AU (1) | AU762351B2 (de) |
CA (1) | CA2356109C (de) |
DE (1) | DE60016560T2 (de) |
DK (1) | DK1141014T3 (de) |
ES (1) | ES2234560T3 (de) |
IL (2) | IL143866A0 (de) |
PT (1) | PT1141014E (de) |
WO (1) | WO2000040613A1 (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7173005B2 (en) * | 1998-09-02 | 2007-02-06 | Antyra Inc. | Insulin and IGF-1 receptor agonists and antagonists |
US6875741B2 (en) * | 1998-09-02 | 2005-04-05 | Renuka Pillutla | Insulin and IGF-1 receptor agonists and antagonists |
IL143866A0 (en) * | 1999-01-06 | 2002-04-21 | Genentech Inc | Insulin-like growth factor (igf) i mutant variants |
US7250950B2 (en) * | 2001-01-29 | 2007-07-31 | Symyx Technologies, Inc. | Systems, methods and computer program products for determining parameters for chemical synthesis |
US20020143725A1 (en) * | 2001-01-29 | 2002-10-03 | Smith Robin Young | Systems, methods and computer program products for determining parameters for chemical synthesis and for supplying the reagents, equipment and/or chemicals synthesized thereby |
US6849718B2 (en) * | 2001-03-20 | 2005-02-01 | Dana Farber Cancer Institute, Inc. | Muteins of hypoxia inducible factor alpha and methods of use thereof |
US20040048925A1 (en) * | 2002-09-09 | 2004-03-11 | Wiley David B. | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
JP2008504002A (ja) | 2003-11-12 | 2008-02-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 新生児Fcレセプター(FcRn)結合ポリペプチド改変体、ダイマーFc結合タンパク質、およびそれらに関連する方法 |
US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
EP1674113A1 (de) * | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Konjugate von insulinähnlichem Wachstumfaktor-1 und Poly(Ethylenglykol) |
MY146381A (en) * | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
DK1838736T3 (da) | 2005-01-05 | 2013-06-03 | Biogen Idec Inc | Cripto-bindende molekyler |
PT2241575E (pt) * | 2005-01-07 | 2015-09-16 | Regeneron Pharma | Polipéptidos de fusão que contêm o igf-1 e utilizações terapêuticas desses polipéptidos |
TWI406870B (zh) * | 2005-02-21 | 2013-09-01 | Chugai Pharmaceutical Co Ltd | A method of making a protein using hamster IGF-1 |
BRPI0712052A2 (pt) * | 2006-06-09 | 2012-01-10 | Novartis Ag | polipeptìdeos de fator de crescimento tipo insulina estabilizados |
CL2007002502A1 (es) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
CA2658736C (en) * | 2006-08-31 | 2014-08-12 | F. Hoffman-La Roche Ag | Method for the production of insulin-like growth factor-i |
ES2548009T3 (es) | 2007-01-25 | 2015-10-13 | F. Hoffmann-La Roche Ag | Uso de IGFBP-7 en la evaluación de la insuficiencia cardíaca |
AU2008223541B2 (en) * | 2007-03-02 | 2012-04-05 | Amgen Inc. | Methods and compositions for treating tumor diseases |
WO2008153929A1 (en) * | 2007-06-08 | 2008-12-18 | Massachusetts Institute Of Technology | Igf for the treatment of rett syndrome and synaptic disorders |
JP5173018B2 (ja) * | 2008-04-03 | 2013-03-27 | エフ.ホフマン−ラ ロシュ アーゲー | 神経筋障害の処置のためのpeg化igf−i変異体の使用 |
ATE533060T1 (de) * | 2008-04-03 | 2011-11-15 | Hoffmann La Roche | Assays mit pegylierten insulinähnlichen wachstumsfaktoren |
PL219335B1 (pl) * | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
UA103104C2 (ru) * | 2009-07-22 | 2013-09-10 | Ипсен Фарма С.А.С. | Аналоги инсулиноподобного фактора роста-1 (igf-1), содержащие аминокислотную замену в положении 59 |
SG178483A1 (en) | 2009-09-10 | 2012-04-27 | Lonza Biologics Plc | Method and system for polypeptide purification |
US20110152188A1 (en) * | 2009-12-23 | 2011-06-23 | Hanns-Christian Mahler | Pharmaceutical compositions of igf/i proteins |
NZ605400A (en) | 2010-07-09 | 2015-05-29 | Biogen Idec Hemophilia Inc | Chimeric clotting factors |
US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
EA201491346A1 (ru) | 2012-01-10 | 2014-11-28 | Байоджен Айдек Ма Инк. | Усиление транспорта терапевтических молекул через гематоэнцефалический барьер |
MY174820A (en) | 2012-12-18 | 2020-05-17 | Novartis Ag | Stabilized insulin-like growth factor polypeptides |
EP2968498A4 (de) | 2013-03-15 | 2016-09-07 | Biogen Ma Inc | Faktor-ix-polypeptidformulierungen |
CN104293766A (zh) * | 2013-07-15 | 2015-01-21 | 四川农业大学 | 山羊IGFBP3基因cDNA编码序列克隆的方法 |
BR112016005716A2 (pt) | 2013-10-02 | 2017-09-12 | Nat Institutes Of Health | miméticos de fator de crescimento semelhante à insulina para uso em terapia |
UY35874A (es) | 2013-12-12 | 2015-07-31 | Novartis Ag | Un proceso para la preparación de una composición de proteínas pegiladas |
CA2937168A1 (en) | 2014-01-20 | 2015-07-23 | Hanmi Pharm. Co., Ltd. | Long-acting insulin and use thereof |
JP2017510622A (ja) | 2014-01-27 | 2017-04-13 | ノバルティス アーゲー | 筋萎縮を予測するバイオマーカー、方法および使用 |
AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
AR100695A1 (es) | 2014-05-30 | 2016-10-26 | Hanmi Pharm Ind Co Ltd | Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón |
MA41586A (fr) | 2015-02-04 | 2017-12-13 | Hoffmann La Roche | Oligomères antisens de la protéine tau et leurs utilisations |
CN115181778A (zh) | 2015-02-04 | 2022-10-14 | 百时美施贵宝公司 | 选择治疗性分子的方法 |
UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
EP3517544A4 (de) | 2016-09-23 | 2020-06-03 | Hanmi Pharm. Co., Ltd. | Insulinanalogon mit reduzierter bindungskraft an den insulinrezeptor und verwendung davon |
AR111341A1 (es) | 2017-03-23 | 2019-07-03 | Hanmi Pharm Ind Co Ltd | Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo |
CN117384275B (zh) * | 2023-12-13 | 2024-03-15 | 北京科为博生物科技有限公司 | 胰岛素样生长因子突变体igf1m及其应用 |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4411890A (en) * | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
US3721252A (en) * | 1971-04-01 | 1973-03-20 | Catheter And Instr Corp | Spring guide washer |
US4511503A (en) * | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
IL71991A (en) | 1983-06-06 | 1994-05-30 | Genentech Inc | Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes |
WO1985000831A1 (en) | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of insulin-like growth factor |
ATE81779T1 (de) | 1985-08-22 | 1992-11-15 | Gropep Pty Ltd | Peptidanalogedes insulinaehnlichen wachstumsfaktors-1 bei saeugetieren. |
PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
SE8505922D0 (sv) | 1985-12-13 | 1985-12-13 | Kabigen Ab | Construction of an igg binding protein to facilitate downstream processing using protein engineering |
DE3881801T2 (de) | 1987-04-06 | 1993-12-23 | Celtrix Pharma | Menschliche somatomedin-träger-protein-untereinheiten und verfahren zu ihrer herstellung. |
ES2007309T3 (es) | 1987-04-23 | 1994-11-01 | Monsanto Co | Secrecion del factor de crecimiento insulinoide 1 en e.coli. |
SE8703625D0 (sv) * | 1987-09-18 | 1987-09-18 | Kabivitrum Ab | New medical use |
US4876242A (en) * | 1987-09-21 | 1989-10-24 | Merck & Co., Inc. | Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast |
US5470828A (en) | 1987-12-24 | 1995-11-28 | Gropep Pty. Ltd. | Peptide analogs of insulin-like growth factor II |
DE3852636T2 (de) | 1987-12-24 | 1995-05-04 | Gropep Pty Ltd | Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2). |
EP0327503B1 (de) | 1988-02-05 | 1993-03-10 | Ciba-Geigy Ag | Verwendung von IGF I zur Herstellung eines Präparates für die Behandlung von Nierenkrankheiten |
US4988675A (en) * | 1988-02-05 | 1991-01-29 | Ciba-Geigy Corporation | Method for preventing secondary effects |
DK131988A (da) | 1988-03-11 | 1989-09-12 | Erasmus University | Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur |
US5258287A (en) | 1988-03-22 | 1993-11-02 | Genentech, Inc. | DNA encoding and methods of production of insulin-like growth factor binding protein BP53 |
AU1955388A (en) | 1988-04-12 | 1989-11-03 | Synergen, Inc. | Method for potentiating and inhibiting insulin-like growth factor activity |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
US5534617A (en) * | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
GB8826451D0 (en) | 1988-11-11 | 1988-12-14 | Sandoz Ltd | Improvements in/relating to organic compounds |
IL92816A0 (en) | 1988-12-22 | 1990-09-17 | Biogrowth Inc | Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides |
CA2007886A1 (en) | 1989-01-17 | 1990-07-17 | Marvin L. Bayne | Human insulin-like growth factor analogs with reduced binding to 28 k igf binding proteins and their production in yeast |
US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
US5652214A (en) * | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
GB8920381D0 (en) | 1989-09-08 | 1989-10-25 | Greater Glasgow Health Board | Treatment of insulin-resistant diabetes |
ZA9010332B (en) | 1989-12-22 | 1991-08-28 | Ciba Geigy | Method of reducing or preventing adverse effect of steroid therapy and compositions therefor |
NZ236618A (en) | 1990-01-03 | 1997-06-24 | Ciba Geigy Ag | Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound |
US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
US5374620A (en) * | 1990-06-07 | 1994-12-20 | Genentech, Inc. | Growth-promoting composition and its use |
US5364839A (en) | 1990-06-18 | 1994-11-15 | Genetics Institute, Inc. | Osteoinductive pharmaceutical formulations |
US5210017A (en) * | 1990-11-19 | 1993-05-11 | Genentech, Inc. | Ligand-mediated immunofunctional hormone binding protein assay method |
US5593844A (en) * | 1990-11-19 | 1997-01-14 | Genentech, Inc. | Ligand-mediated immunofunctional hormone binding protein assay method |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
SE9100099D0 (sv) | 1991-01-11 | 1991-01-11 | Kabi Pharmacia Ab | Use of growth factor |
US5206023A (en) | 1991-01-31 | 1993-04-27 | Robert F. Shaw | Method and compositions for the treatment and repair of defects or lesions in cartilage |
US5187151A (en) * | 1991-02-12 | 1993-02-16 | Genentech, Inc. | Use of binding protein with igf-i as an anabolic growth promoting agent |
JP4146512B2 (ja) | 1991-03-01 | 2008-09-10 | ダイアックス コープ. | 小型タンパク質 |
US5206235A (en) * | 1991-03-20 | 1993-04-27 | Merck & Co., Inc. | Benzo-fused lactams that promote the release of growth hormone |
US5202119A (en) * | 1991-06-28 | 1993-04-13 | Genentech, Inc. | Method of stimulating immune response |
EP0597033B1 (de) | 1991-08-01 | 1997-04-09 | Genentech, Inc. | IGF-I zur Verbesserung der neuronale Lage |
US6310040B1 (en) | 1991-11-08 | 2001-10-30 | Cephalon, Inc. | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs |
TW267102B (de) | 1992-03-13 | 1996-01-01 | Ciba Geigy | |
SE9201573D0 (sv) * | 1992-05-19 | 1992-05-19 | Kabi Pharmacia Ab | Use of igf-1 |
JP3623502B2 (ja) | 1992-06-12 | 2005-02-23 | セファロン,インコーポレイテッド | 末梢神経障害の予防および治療 |
NZ255461A (en) | 1992-08-20 | 1996-12-20 | Biotechnology & Biolog Science | Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity |
US5273961A (en) | 1992-09-22 | 1993-12-28 | Genentech, Inc. | Method of prophylaxis of acute renal failure |
US5342763A (en) * | 1992-11-23 | 1994-08-30 | Genentech, Inc. | Method for producing polypeptide via bacterial fermentation |
SG46612A1 (en) | 1992-12-02 | 1998-02-20 | Hoechst Ag | Process for obtaining proinsulin in processing correctly linked cystine bridges |
WO1994016722A1 (en) | 1993-01-25 | 1994-08-04 | The Beth Israel Hospital Association | Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties |
JPH09500088A (ja) | 1993-01-29 | 1997-01-07 | アムジェン ボールダー インコーポレイテッド | 創傷治癒用組成物 |
US5457109A (en) | 1993-09-15 | 1995-10-10 | Warner-Lambert Company | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
IL112111A (en) | 1993-12-23 | 2000-07-16 | Novo Nordisk As | Peptides having growth hormone releasing properties and pharmaceutical compositions containing them |
NZ277486A (en) | 1993-12-23 | 1997-03-24 | Novo Nordisk As | Synthetic peptides with growth hormone releasing properties |
US5597700A (en) | 1994-04-28 | 1997-01-28 | California Research, Llc | Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method |
US5444047A (en) * | 1994-06-16 | 1995-08-22 | Dipasquale; Gene | Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I |
SE9402331D0 (sv) | 1994-07-01 | 1994-07-01 | Pharmacia Ab | New use |
SE9402370D0 (sv) | 1994-07-04 | 1994-07-04 | Pharmacia Ab | Use of IGF-I |
HRP940432B1 (en) | 1994-08-05 | 2003-10-31 | Pliva Pharm & Chem Works | Dna sequences encoding biosynthetic insulin precursors and process for preparation of insulin |
US5712249A (en) * | 1994-09-08 | 1998-01-27 | Ciba-Geigy Corporation | Use of insulin-like growth factors I and II for inhibition of inflammatory response |
US5798337A (en) | 1994-11-16 | 1998-08-25 | Genentech, Inc. | Low molecular weight peptidomimetic growth hormone secretagogues |
SE9501472D0 (sv) | 1995-04-21 | 1995-04-21 | Pharmacia Ab | Truncated IGF-I |
US5622932A (en) * | 1995-05-05 | 1997-04-22 | Eli Lilly And Company | IGF-1 superagonists |
US5741776A (en) | 1995-05-22 | 1998-04-21 | Genentech, Inc. | Method of administration of IGF-I |
US5565428A (en) | 1995-05-22 | 1996-10-15 | Genentech, Inc. | Method of administration of IGF-I |
KR100543190B1 (ko) | 1995-05-26 | 2006-06-23 | 떼라떼끄놀로지 인코퍼레이티드 | 향상된생물학적효능을갖는키메라성지방체-프로-지알에프유사체 |
EP2338897A1 (de) | 1995-06-07 | 2011-06-29 | Glaxo Group Limited | Peptide und Verbindungen, die einen Thrombopoietin-Rezeptor binden |
YU34196A (sh) | 1995-06-07 | 1999-03-04 | Glaxo Group Limited | Peptidi i jedinjenja koja se vezuju za receptor |
US5958872A (en) | 1996-04-01 | 1999-09-28 | Apoptosis Technology, Inc. | Active survival domains of IGF-IR and methods of use |
AU2676297A (en) | 1996-04-17 | 1997-11-07 | Neurocrine Biosciences, Inc. | Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor |
CA2265972A1 (en) | 1996-09-16 | 1998-03-26 | Philip D. Acott | Use of igf-i for the treatment of polycystic kidney disease and related indications |
JP2001503064A (ja) | 1996-11-06 | 2001-03-06 | ジェネンテク,インコーポレイテッド | 拘束されたラセンペプチドとその製法 |
WO1998029451A1 (fr) | 1996-12-27 | 1998-07-09 | Daiichi Pharmaceutical Co., Ltd. | Procede pour elever la concentration de facteur de croissance libre apparente a l'insuline |
US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
PE79099A1 (es) | 1997-06-13 | 1999-08-24 | Lilly Co Eli | Formulaciones de insulina estables |
DE19757250A1 (de) | 1997-12-22 | 1999-07-01 | Forssmann Wolf Georg Prof Dr | Insulin-like growth factor binding protein und seine Verwendung |
WO1999051262A2 (en) | 1998-04-03 | 1999-10-14 | Chiron Corporation | Use of igfi for treating articular cartilage disorders |
ATE303159T1 (de) | 1998-10-02 | 2005-09-15 | Celtrix Pharma | Null igf zur krebsbehandlung |
WO2000023469A2 (en) | 1998-10-16 | 2000-04-27 | Musc Foundation For Research Development | Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof |
IL143834A0 (en) | 1999-01-06 | 2002-04-21 | Genentech Inc | Insulin-like growth factor (igf) i mutant variants |
IL143866A0 (en) | 1999-01-06 | 2002-04-21 | Genentech Inc | Insulin-like growth factor (igf) i mutant variants |
JP2003518917A (ja) | 1999-05-19 | 2003-06-17 | ゼンコー | 糖尿病の処置に有用なインシュリン様活性を有する新規タンパク質 |
EP2043676A2 (de) | 2006-07-06 | 2009-04-08 | Molecular Logix, Inc. | Rezeptorantagonisten des insulinähnlichen wachstumsfaktors 1 |
-
2000
- 2000-01-05 IL IL14386600A patent/IL143866A0/xx unknown
- 2000-01-05 JP JP2000592321A patent/JP3971108B2/ja not_active Expired - Lifetime
- 2000-01-05 CA CA002356109A patent/CA2356109C/en not_active Expired - Lifetime
- 2000-01-05 DE DE60016560T patent/DE60016560T2/de not_active Expired - Lifetime
- 2000-01-05 AU AU22245/00A patent/AU762351B2/en not_active Expired
- 2000-01-05 AT AT00901397T patent/ATE284415T1/de active
- 2000-01-05 DK DK00901397T patent/DK1141014T3/da active
- 2000-01-05 EP EP00901397A patent/EP1141014B1/de not_active Expired - Lifetime
- 2000-01-05 WO PCT/US2000/000199 patent/WO2000040613A1/en active IP Right Grant
- 2000-01-05 PT PT00901397T patent/PT1141014E/pt unknown
- 2000-01-05 ES ES00901397T patent/ES2234560T3/es not_active Expired - Lifetime
- 2000-01-05 US US09/477,924 patent/US6403764B1/en not_active Expired - Lifetime
-
2001
- 2001-06-20 IL IL143866A patent/IL143866A/en not_active IP Right Cessation
- 2001-12-19 US US10/028,410 patent/US7105167B2/en not_active Expired - Lifetime
-
2006
- 2006-06-21 JP JP2006171517A patent/JP2006328074A/ja active Pending
- 2006-08-28 US US11/512,046 patent/US8097587B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ES2234560T3 (es) | 2005-07-01 |
ATE284415T1 (de) | 2004-12-15 |
US6403764B1 (en) | 2002-06-11 |
EP1141014A1 (de) | 2001-10-10 |
US20110003746A1 (en) | 2011-01-06 |
CA2356109C (en) | 2008-04-22 |
IL143866A0 (en) | 2002-04-21 |
WO2000040613A1 (en) | 2000-07-13 |
DE60016560T2 (de) | 2005-12-15 |
CA2356109A1 (en) | 2000-07-13 |
IL143866A (en) | 2009-11-18 |
DE60016560D1 (de) | 2005-01-13 |
AU762351B2 (en) | 2003-06-26 |
US7105167B2 (en) | 2006-09-12 |
AU2224500A (en) | 2000-07-24 |
PT1141014E (pt) | 2005-04-29 |
EP1141014B1 (de) | 2004-12-08 |
JP3971108B2 (ja) | 2007-09-05 |
US8097587B2 (en) | 2012-01-17 |
JP2006328074A (ja) | 2006-12-07 |
US20020160955A1 (en) | 2002-10-31 |
JP2002535968A (ja) | 2002-10-29 |
WO2000040613A9 (en) | 2001-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1141014T3 (da) | Insulinlignende vækstfaktor (IGF) i mutantvariant | |
DE69434817D1 (de) | Protease varianten | |
DK1141015T3 (da) | Insulin-lignende vækstfaktor (IGF) I-mutantvarianter | |
AUPP051497A0 (en) | Antimicrobial peptides | |
BR9811187A (pt) | Composições detergentes compreendendo uma mananase e uma protease | |
HK1037196A1 (en) | Analogues of glp-1. | |
IL143481A0 (en) | Glp-1 analogues | |
EA200300026A1 (ru) | Аналоги глюкагоноподобного пептида-1 | |
MXPA02011899A (es) | Agentes secretagogos de hormona de crecimiento. | |
ZA992448B (en) | Quinoxalinones as serine protease inhibitors. | |
DK1653989T3 (da) | Antibakteriel sammensætning især mod gramnegative bakterier og som omfatter et peptid og et fortrinsvist hydrofobt antibakterielt middel | |
BR9407502A (pt) | Variantes subtilisina bpn com adsorção diminuída e hidrólise aumentada | |
UA50808C2 (uk) | Композиція для лікування респіраторного дистрес-синдрому дорослих або респіраторного дистрес-синдрому новонароджених | |
GB9907683D0 (en) | Substituted azetidin-2-ones as cysteine protease inhibitors | |
LT99131A (en) | Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, acitivity | |
ATE210149T1 (de) | Entzündungshemmende zusammensetzung und methode, in welchen des-tyr dynorphin und analoge benutzt werden | |
NZ336793A (en) | Method for stabilizing peptides by adding an organic acid and then lyophilizing the peptide mixture | |
ID28463A (id) | KOMPOSISI DENGAN KEMURNIAN TINGGI YANG TERDIRI DARI (7α, 17α)-17-HIDROKSI-7-METIL-19-NOR-17-PREGN-5(10)-EN-20-IN-3-ON | |
NO971508L (no) | Analoger av sur fibroblastvekstfaktor med forökt stabilitet og biologisk aktivitet | |
EP1074264A4 (de) | Inhibitoren für die gefässneubildung | |
JO1992B1 (en) | Fixed pharmaceutical compounds based on the derivatives of quinpristine and dalphopristine materials and their preparation process | |
PL351140A1 (en) | Lyophilisates with improved reconstitutibility | |
AU3494093A (en) | S-lipophilic aliphatic carbonyl {n-mercaptoacyl-(amino acid or peptide)} compounds as antihypertensive agents | |
BR0209144A (pt) | Composição associadas ao fator de crescimento de fibroblasto humano | |
EP1359159A3 (de) | GLP-1 Analoge |